Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR HFA versus RAYOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR HFA versus RAYOS.
ADVAIR HFA vs RAYOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADVAIR HFA is a combination of fluticasone propionate, a corticosteroid that reduces inflammation by inhibiting multiple inflammatory cell types and mediators, and salmeterol, a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing cAMP levels.
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
2 inhalations (fluticasone 230 mcg/salmeterol 21 mcg per inhalation) twice daily, approximately 12 hours apart, via oral inhalation. Maximum: 2 inhalations twice daily.
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
None Documented
None Documented
Fluticasone propionate: 7.8 hours (inhalation), prolonged in hepatic impairment. Salmeterol: 5.5 hours.
2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing.
Fluticasone propionate: Renal <5%, fecal (primarily as metabolites) ~90%. Salmeterol: Renal 25% (as metabolites), fecal 60%.
Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount.
Category C
Category C
Corticosteroid/LABA Combination
Corticosteroid